These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 25637161

  • 1. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M, Fulda S.
    Cancer Lett; 2015 Apr 28; 360(1):1-9. PubMed ID: 25637161
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
    Avniel-Polak S, Leibowitz G, Riahi Y, Glaser B, Gross DJ, Grozinsky-Glasberg S.
    Neuroendocrinology; 2016 Oct 10; 103(6):724-37. PubMed ID: 26619207
    [Abstract] [Full Text] [Related]

  • 13. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
    Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL.
    Toxicol Lett; 2013 Jul 18; 220(3):267-76. PubMed ID: 23651616
    [Abstract] [Full Text] [Related]

  • 14. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.
    Oncotarget; 2015 Nov 03; 6(34):35202-17. PubMed ID: 26460954
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C, Dahlhaus M, Glass A, Fischer K, Lange S, Freund M, Junghanss C.
    Anticancer Res; 2012 Feb 03; 32(2):463-74. PubMed ID: 22287733
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 03; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Jul 03; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.